Investigational drug · Phase 2
SYS6006
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "SYS6006"
First trial start
2026
May 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6006" as an intervention, largest first.
- Effectiveness of a Second COVID-19 Vaccine Booster in Chinese AdultsPivotal-lookingStatus unknown
Jiangsu Province Centers for Disease Control and PreventionResearch network
NCT05855408 · 10,000 participants (planned) · Start May 18, 2023 · Primary completion May 18, 2024
Drug: Intramuscularly administered Ad5-nCoV vaccine; Aerosolized Ad5-nCoV and 2 more · For: COVID-19
Sites: Nanjing, China
Jiangsu Province Centers for Disease Control and PreventionResearch network
NCT07834073 · 2,052 participants · Start May 23, 2023 · Primary completion Feb 28, 2024
Drug: SYS6006 · For: COVID-19; SARS-CoV-2 Infection
Sites: Nanjing, China
Zhongnan HospitalAcademic, hospital or other
NCT05492643 · 1,000 participants (planned) · Start Aug 13, 2022 · Primary completion Feb 27, 2023
Drug: one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006) · For: SARS-CoV-2; Safety; Immunotoxicity
Sites: Wuhan, China
- A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or MorePivotal-lookingStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05439824 · 450 participants · Start Jun 28, 2022 · Primary completion Jan 12, 2023
Drug: SYS6006 20 μg; SYS6006 30 μg and 1 more · For: SARS-CoV-2 Infection
Sites: Shijiazhuang, China; Nanjing, China
- SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid TumorsPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07622225 · 264 participants (planned) · Start May 29, 2026 · Primary completion Dec 31, 2028
Drug: SYS6006; Enlonstobart · For: Advanced Solid Tumors
- A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.Status unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05354089 · 40 participants (planned) · Start Apr 27, 2022 · Primary completion Jul 9, 2022
Drug: 20 μg dose of SYS6006; 30 μg dose of SYS6006 and 1 more · For: SARS-CoV-2
Sites: Nanjing, China; Hangzhou, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05354063 · 40 participants (planned) · Start Jun 1, 2022 · Primary completion Sep 5, 2022
Drug: 20 μg dose of SYS6006; 30 μg dose of SYS6006 and 1 more · For: SARS-CoV-2
Sites: Nanjing, China; Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C, Qiu Y, Wang J, et al. · Emerg Microbes Infect 2024
- Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs.
Huo H, Wang J, Li C, et al. · Front Cell Infect Microbiol 2024
- Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
Su YW, Qiu YZ, Wang YH, et al. · Vaccine 2024
- Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
Jin F, Qiu Y, Wu Z, et al. · Vaccine 2024
- Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.
Huang J, Qiu Y, Luo L, et al. · J Med Virol 2024
- Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Chen GL, Qiu YZ, Wu KQ, et al. · Hum Vaccin Immunother 2023
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.